243 related articles for article (PubMed ID: 9863301)
21. Understanding multiple sclerosis: new immunologic insights and prospects for specific therapy.
Ransohoff RM
Compr Ther; 1991 Nov; 17(11):3-6. PubMed ID: 1799959
[No Abstract] [Full Text] [Related]
22. Future immunotherapies in multiple sclerosis.
Blevins G; Martin R
Semin Neurol; 2003 Jun; 23(2):147-58. PubMed ID: 12894380
[TBL] [Abstract][Full Text] [Related]
23. Insights for practice: where mechanism of action meets patient management.
Lisak RP; Korngold S
Neurology; 2010 Jan; 74 Suppl 1():S70-3. PubMed ID: 20038766
[No Abstract] [Full Text] [Related]
24. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
Lim ET; Giovannoni G
Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
[TBL] [Abstract][Full Text] [Related]
25. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
26. Is damage in central nervous system due to inflammation?
Chavarria A; Alcocer-Varela J
Autoimmun Rev; 2004 Jun; 3(4):251-60. PubMed ID: 15246020
[TBL] [Abstract][Full Text] [Related]
27. Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting.
Stinissen P; Raus J
Acta Neurol Belg; 1999 Mar; 99(1):65-9. PubMed ID: 10218096
[TBL] [Abstract][Full Text] [Related]
28. The immunological basis for treatment of multiple sclerosis.
Holmøy T; Vartdal F
Scand J Immunol; 2007 Oct; 66(4):374-82. PubMed ID: 17850581
[TBL] [Abstract][Full Text] [Related]
29. Rationale for immunotherapy in multiple sclerosis.
Whitaker JN
Ann Neurol; 1994; 36 Suppl():S103-7. PubMed ID: 8017867
[TBL] [Abstract][Full Text] [Related]
30. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
31. Multiple sclerosis: MHC associations and therapeutic implications.
Holmes S; Friese MA; Siebold C; Jones EY; Bell J; Fugger L
Expert Rev Mol Med; 2005 Feb; 7(3):1-17. PubMed ID: 15710050
[TBL] [Abstract][Full Text] [Related]
32. Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system.
Kawanokuchi J; Mizuno T; Kato H; Mitsuma N; Suzumura A
Neuropharmacology; 2004 Apr; 46(5):734-42. PubMed ID: 14996551
[TBL] [Abstract][Full Text] [Related]
33. Multiple sclerosis.
Hafler DA; Slavik JM; Anderson DE; O'Connor KC; De Jager P; Baecher-Allan C
Immunol Rev; 2005 Apr; 204():208-31. PubMed ID: 15790361
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy of multiple sclerosis.
Weiner HL; Hafler DA
Ann Neurol; 1988 Mar; 23(3):211-22. PubMed ID: 3288084
[TBL] [Abstract][Full Text] [Related]
35. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.
Madsen LS; Andersson EC; Jansson L; krogsgaard M; Andersen CB; Engberg J; Strominger JL; Svejgaard A; Hjorth JP; Holmdahl R; Wucherpfennig KW; Fugger L
Nat Genet; 1999 Nov; 23(3):343-7. PubMed ID: 10610182
[TBL] [Abstract][Full Text] [Related]
36. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Youssef S; Stüve O; Patarroyo JC; Ruiz PJ; Radosevich JL; Hur EM; Bravo M; Mitchell DJ; Sobel RA; Steinman L; Zamvil SS
Nature; 2002 Nov; 420(6911):78-84. PubMed ID: 12422218
[TBL] [Abstract][Full Text] [Related]
37. Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.
Kohm AP; Turley DM; Miller SD
Int Rev Immunol; 2005; 24(5-6):361-92. PubMed ID: 16318987
[TBL] [Abstract][Full Text] [Related]
38. Antigen-specific therapies in multiple sclerosis.
Sospedra M; Martin R
Int Rev Immunol; 2005; 24(5-6):393-413. PubMed ID: 16318988
[TBL] [Abstract][Full Text] [Related]
39. [Multiple sclerosis--recent advances in pathogenesis and treatment].
Itoyama Y; Fujihara K; Nakashima I; Misu T; Fujimori T; Sato S
No To Shinkei; 2002 Jan; 54(1):5-21. PubMed ID: 11868352
[No Abstract] [Full Text] [Related]
40. The use of glatiramer acetate in the treatment of multiple sclerosis.
Wolinsky JS
Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
